Bringing JUPITER down to earth

The Lancet

Volumn 373, Issue 9670, 2009, Pages 1147-1148

  Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; FITNESS; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK REDUCTION; WEIGHT REDUCTION;

EID: 63349111910     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60448-7     Document Type: Note

References (12)

1. Ridker P.M., Danielson E., Fonseca F., et al., on behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.1016/S0140-6736(09)60447-5 published online March 29, 2009.
2. Ridker P.M., Danielson E., Fonseca F., et al., for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
3. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
4. 100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
5. Hak A.E., Stehouwer C.D., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19 (1999) 1986-1991
6. Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21 (2001) 961-967
7. Church T.S., Barlow C.E., Earnest C.P., Kampert J.B., Priest E.L., and Blair S.N. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 22 (2002) 1869-1876
8. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
9. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
10. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
11. Després J.-P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
12. Sui X., LaMonte M.J., and Blair S.N. Cardiorespiratory fitness as a predictor of nonfatal cardiovascular events in asymptomatic women and men. Am J Epidemiol 165 (2007) 1413-1423